Abstract
Objectives A screening tool for substance use disorders is most needed for patient care and referral. The study aims to develop the Substance Use Disorder Screening Test (SUDST) to classify the severity of substance use disorders based on the Fifth Edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5).
Methods Eleven items of the SUDST, developed based on the DSM-5, were tested on 207 participants who were receiving treatment for methamphetamine use. Participants were interviewed with the SUDST, the screening test of the Ministry of Public Health Version 2 (V.2), the Mini International Neuropsychiatric Inventory (M.I.N.I) and were clinically diagnosed by attending psychiatrists.
Results Cronbach’s alpha coefficient was 0.79. The SUDST was highly significantly associated with the M.I.N.I., V.2, and the clinical diagnosis (p < 0.001). Factor analysis showed three components: 1) preoccupation and loss of control 2) risky/harmful use and 3) impact to bio-psychosocial aspects. Of the total score of 11, the cut-off points to identify severe, moderate, and mild levels of risk were ≥7, 5-6, and 3-4, respectively with sensitivity = 72.7%-96.5% and specificity = 61.9%-88.7%.
Conclusions The SUDST had high reliability and validity that could be used for screening risk for substance use disorders.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
R.K.’s research career is supported by the Centre for Addiction Studies, Department of Psychiatry, Faculty of Medicine, Chulalongkorn University and the R01 DA037974 and the D43 TW009087/TW/FIC NIH HHS, US. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Not Applicable
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study protocol has been approved by the Ethical Committee of the Princess Mother National Institute on Drug Abuse Treatment (PMNIDAT).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Not Applicable
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Not Applicable
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Not Applicable
Data Availability
Data will be held in a public repository, https://cads.in.th/cads/.
